Table 2.
Adverse events represented in two stages: Stage 1 before vaccination (w−52–w−1), and Stage 2 during vaccination and until the end of study (w0–w28) divided by severity and its relation to the interventions.
| STAGE 1 | RELATED | UNRELATED | ||||||
|---|---|---|---|---|---|---|---|---|
| GRADE 1-2 | 27 | 41 | ||||||
| GRADE 3-4 | 0 | 3 | ||||||
| STAGE 2 | DCV3 | DCV3 + IFNα-2a | PLACEBO | PLACEBO + IFNα-2a | DCV3 | DCV3 + IFNα-2a | PLACEBO | PLACEBO + IFNα-2a |
| GRADE 1-2 | 11 | 16 | 6 | 9 | 16 | 8 | 4 | 11 |
| GRADE 3-4 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| STAGE 1 | No AE related | Seminoma, Subarachnoid hemorrhage, Cataract surgery | ||||||
| STAGE 2 | M. malmoense pneumonia | Ischemic stroke | ||||||
At the end, a description of grade 3–4 adverse events accordingly is included.
IFN, Interferon.